Share Twitter LinkedIn Facebook Email Chuck Wiseman, MD, BriaCell Therapeutics, talks about Rollover Protocol Approval Bria-IMT in combination with a checkpoint inhibitor at Annual Meeting 2018.
Enhertu DESTINY-Breast06 Phase III Study the Impact on HR-Positive, HER2-Low Metastatic Breast Cancer Revealed Breast 4 Mins Read
Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES] Breast 4 Mins Read